Pre-Transplantation Blockade of TNF-α-Mediated Oxygen Species Accumulation Protects Hematopoietic Stem Cells

TAKASHI ISHIDA,a,b,c* SACHIE SUZUKI,d* CHEN-YI LAI, b SATOSHI YAMAZAKI, c SHIGERU KAKUTA, a YOICHIRO IWAKURA, f MASANORI NOJIMA, g YASUO TAKEUCHI, h MASAAKI HIGASHIHARA, a HIROMITSU NAKAUCHI,c,i MAKOTO OTSU b

Key Words. Adult hematopoietic stem cells • Transplantation • Irradiation • TNF-α • Reactive oxygen species • Inflammation • Hematopoietic stem cell transplantation • Bone marrow

INTRODUCTION

Hematopoietic stem cell (HSC) transplantation (HSCT) for malignancy requires toxic pre-conditioning to maximize anti-tumor effects and donor-HSC engraftment. While this induces bone marrow (BM)-localized inflammation, how this BM environmental change affects transplanted HSCs in vivo remains largely unknown. We here report that, depending on interval between irradiation and HSCT, residence within lethally irradiated recipient BM compromises donor-HSC reconstitution ability; (b) elevated levels of TNF-α in inflamed BM is responsible for the effect; (c) TNF-α induces formation of ROS through an NADPH oxidase in donor HSCs, leading to impaired reconstitution ability; (d) Pre-incubation with an antioxidant NAC that suppresses TNF-α-mediated ROS accumulation in HSCs. Transplantation of flow-cytometry—sorted murine HSCs reveals damaging effects of accumulated ROS on HSCs. Short-term incubation either with an specific inhibitor of tumor necrosis factor receptor 1 signaling or an antioxidant N-acetyl-L-cysteine (NAC) prevents TNF-α-mediated ROS accumulation in HSCs. Importantly, pre-transplantation exposure to NAC successfully demonstrates protective effects in inflammatory BM on graft-HSCs, exhibiting better reconstitution capability than that of nonprotected control grafts. We thus suggest that in vivo protection of graft-HSCs from BM inflammation is a feasible and attractive approach, which may lead to improved hematopoietic reconstitution kinetics in transplantation with myeloablative conditioning that inevitably causes inflammation in recipient BM. Stem Cells 2017;35:989–1002

ABSTRACT

Hematopoietic stem cell (HSC) transplantation (HSCT) for malignancy requires toxic pre-conditioning to maximize anti-tumor effects and donor-HSC engraftment. While this induces bone marrow (BM)-localized inflammation, how this BM environmental change affects transplanted HSCs in vivo remains largely unknown. We here report that, depending on interval between irradiation and HSCT, residence within lethally irradiated recipient BM compromises donor-HSC reconstitution ability. Both in vivo and in vitro we demonstrate that, among inflammatory cytokines, TNF-α plays a role in HSC damage: TNF-α stimulation leads to accumulation of reactive oxygen species (ROS) in highly purified hematopoietic stem/progenitor cells (HSCs/HSPCs). Transplantation of flow-cytometry—sorted murine HSCs reveals damaging effects of accumulated ROS on HSCs. Short-term incubation either with an specific inhibitor of tumor necrosis factor receptor 1 signaling or an antioxidant N-acetyl-L-cysteine (NAC) prevents TNF-α-mediated ROS accumulation in HSCs. Importantly, pre-transplantation exposure to NAC successfully demonstrates protective effects in inflammatory BM on graft-HSCs, exhibiting better reconstitution capability than that of nonprotected control grafts. We thus suggest that in vivo protection of graft-HSCs from BM inflammation is a feasible and attractive approach, which may lead to improved hematopoietic reconstitution kinetics in transplantation with myeloablative conditioning that inevitably causes inflammation in recipient BM. Stem Cells 2017;35:989–1002

SIGNIFICANCE STATEMENT

This study shows the following: (a) depending on interval between TBI and HSCT, residence within lethally irradiated recipient BM compromises donor-HSC reconstitution ability; (b) elevated levels of TNF-α in inflamed BM is responsible for the effect; (c) TNF-α induces formation of ROS through an NADPH oxidase in donor HSCs, leading to impaired reconstitution ability; (d) Pre-incubation with an antioxidant NAC that suppresses TNF-α-stimulated ROS production successfully protects transplanted HSCs from BM inflammation. We eventually came up with the proposal of “in vivo stem cell protection” as a novel therapeutic concept in HSCT. These findings have implications for the basic HSC biology and for the improvement of an HSCT outcome for patients.

STEM CELLS 2017;35:989–1002 www.StemCells.com © 2016 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
cytokines can be essential for HSC function [3, 11]. These findings rely on mostly in vitro studies; in vivo effects of cytokines on transplanted wild type HSCs have been difficult to model. Among the above inflammatory cytokines, TNF-α was demonstrated to be a relevant in vivo suppressor of HSCs in the context of transplantation [8]. In this study, HSCs genetically lacking both TNFR-p55 and TNFR-p75 were shown to have competitive advantage over wild type counterparts upon transplantation into lethally irradiated recipients. These results clearly indicate that negative effects are mediated by TNF-α on post-transplant hematopoiesis in irradiated hosts. This may translate into the idea that blockade of such negative effects will lead to improved HSC transplantation outcomes [8, 12].

To develop a clinically relevant measure to protect HSCs without genetic modification from deleterious effects inherent to post-transplantation environment, we thought it essential to know if the impairment of HSC function could occur even within a short-term period after transplantation. This is critical because if that is the case, a protective measure will be still effective for HSCs with only short-acting treatment. We therefore have developed a series of novel in vivo systems that allow testing the effects of BM inflammation on HSCs at transplantation and during engraftment ("graft-HSCs"). Of note is a short-term HSC exposure assay in which graft-HSCs are exposed only for a limited period to the inflammatory BM environment generated by preconditioning treatments. Using these assays, we indeed identified elevated levels of TNF-α in inflamed BM and demonstrated that these, by inducing formation of reactive oxygen species (ROS), impaired reconstitution ability of donor HSCs in secondary transplantation. We further demonstrated that protection was feasible by pre-incubation of HSCs with an antioxidant N-acetyl-L-cysteine (NAC) against ROS accumulation mediated by TNF-α in inflamed BM, leading to improved graft-HSC reconstitution capability. We propose "stem cell protection" as a novel therapeutic concept in HSCT.

**Materials and Methods**

**Mice**

C57BL/6 (Ly5.2<sup>+</sup>, B6-Ly5.2) mice were purchased from Japan SLC (Shizuoka, Japan). Ly5.1<sup>+</sup> congenic B6 (B6-Ly5.1) and Ly5.1<sup>−</sup>/5.2<sup>+</sup> B6 F1 (B6-Ly5.1/5.2) mice were purchased from Sankyo Laboratory Service (Tsukuba, Japan). TNF-α knockout B6 (Ly5.2<sup>+</sup>) mice were provided by the Laboratory of Molecular Pathogenesis, Center for Experimental Medicine, Institute of Medical Science, University of Tokyo.

**Purification of Mouse Hematopoietic Stem/Progenitor Cells**

Purification of mouse hematopoietic stem/progenitor cells (HSPCs), phenotypically defined as KSL cells (cKit<sup>+</sup>, Sca-1<sup>−</sup>, lineage-marker<sup>−</sup>), is described [13, 14]. Where indicated, highly purified HSCs were used (CD34<sup>+</sup>low cells among the KSL fraction: CD34<sup>−</sup> KSL cells), with the purity being comparable to that of SLAM-HSCs [15] due to our strict gating strategy [16]. Briefly, BM cells isolated from femora, tibiae, and pelvic bones of adult mice (8-12 weeks) were incubated with allopheycocyanin (APC)-conjugated anti-c-Kit monoclonal Abs (BD Biosciences, San Jose, CA). The cells expressing c-Kit were enriched using columns after incubation with anti-APC magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). These cells were stained using a cocktail of biotinylated mAbs specific for the antigens CD4, CD8, B220, IL-7R, Gr-1, Mac-1, and Ter-119 (BD Biosciences), with phycoerythrin (PE)-conjugated anti-Sca-1 (eBioscience, San Diego, CA) and APC-conjugated anti-c-Kit (BD Biosciences) mAbs and APC/cyanin7 (Cy7)-streptavidin (eBioscience). FITC-anti-CD34 mAb (eBioscience) was added to obtain CD34<sup>+</sup> KSL cells. Cells were sorted on a FACS Aria II cell sorter (BD Biosciences).

**Transplantation**

Recipient mice fed with acidified water (pH 2.5) for over 1 week before BMT were lethally irradiated with a total dose of 9.8 Gy (2 split doses 3 hours apart) or a single dose of 9.5 Gy at stated times and were intravenously transplanted with cells as specified. After transplantation, they were fed with acidified water containing enflaxcin (Baytril; Bayer Animal Health, Leverkusen, Germany) for at least 2 wks. Serial transplantation was performed either with unfractionated BM cells from primary recipients in a noncompetitive manner or with sorted cell populations in a competitive manner.

**Treatment of Mouse Hematopoietic Stem/Progenitor Cells**

For in vitro ROS detection, 3,000 KSL cells were sorted into individual wells of a 96-well plate containing 200 μl of S-clove (Eidai, Tokyo, Japan) supplemented with 1% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO), 1% penicillin-streptomycin-glutamine mix (PSG; Life Technologies, Carlsbad, CA), 100 ng/ml murine stem cell factor (SCF), and 100 ng/ml murine thrombopoietin (TPO) with or without murine TNF-α (all Peprotech, Rocky Hill, NJ).

**Competitive Repopulation Assays**

Competitive repopulation assays were performed using a Ly5-congenic mouse system as described [17]. Freshly isolated CD34<sup>+</sup> KSL cells from B6-Ly5.1 mice or cultured CD34<sup>+</sup> KSL cells, in the numbers shown, were transplanted into lethally irradiated B6-Ly5.2 mice together with 2 × 10<sup>5</sup> or 5 × 10<sup>5</sup> whole BM competitor cells from B6-Ly5.1/5.2 F1 mice. Intervals between TBI and transplantation were as stated. Peripheral blood cells of the recipient mice were analyzed at the indicated times. After treatment with ACK lysis buffer (NH₄Cl 8,024 mg/l, KHCO₃ 1,001 mg/l, EDTA.Na₂ 2H₂O 3.722 mg/l), the nucleated cells were stained with the following mAbs: FITC-conjugated anti-CD45.2 (Ly5.2, BioLegend), PE/Cy7-conjugated anti-CD45.1 (Ly5.1, eBioscience), PE-conjugated anti-Mac1 (eBioscience), PE-conjugated anti-Gr-1 (eBioscience), APC/Cy7-conjugated anti-CD45R/B220 (eBioscience), APC-conjugated anti-CD4 (BioLegend), and APC-conjugated anti-CD8a (BioLegend). Donor chimerism was determined as the percentage of Ly5.1<sup>+</sup> cells within each cell population (Ly5.1<sup>+</sup> / Ly5.1<sup>−</sup>/Ly5.2<sup>+</sup>) using a FACS Canto flow cytometer (BD Biosciences) and a FlowJo software (TreeStar, Ashland, OR).

**In vivo HSC Protection Transplantation Assays**

Test KSL cells (B6-Ly5.1, male, 8 weeks) were directly sorted into 96-well round-bottom plates at 1,000 cells per well. Each well contained S-clove ± 1% BSA with SCF and TPO (100 ng/ml) as a basal medium. Plates were incubated at 37°C, 5% CO₂ for 4 hours, with control wells containing vehicle alone (nonprotected) and other wells containing NAC (Sigma-Aldrich) at either

© 2016 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

STEM CELLS

HSC Protection from Inflammation in Recipient BM
0.1 mM or 4 mM (protected). These cells were combined with fresh (nonprotected) $1 \times 10^6$ unfractionated BM cells (B6-Ly5.1/5.2, male, 8 weeks), and transplanted into recipient mice ($n = 8$, B6-Ly5.2, female, 8 weeks). In these particular assays, recipient mice were lethally irradiated (4.75 Gy × 2) 2 days before transplantation. For secondary transplantation, BM cells were collected at 20 weeks from all available primary recipients in each group. These cells were pooled, and transplanted into lethally irradiated mice (each received cells corresponding to ~70% BM cells in a single femur of primary recipient mice; $n = 8$, B6-Ly5.2).

**Isolation of BM Stromal Cells**

To assess induction of gene expression after irradiation, stromal cells were isolated from BM samples as described [18]. Briefly, femora and tibiae obtained from BM mice (6 males) either nonirradiated or after 9.5 Gy irradiation, at indicated times were cut into small fragments and digested for 30 minutes with 0.2% collagenase type 1 (Wako, Tokyo, Japan). After removal of undigested materials, the cell suspension was collected and treated with a hemolysis buffer. Hematopoietic cells containing residual erythrocytes were removed by a magnetic separator after incubating cells with biotin-anti-CD45.2 and -Ter-119 mAbs (e-Bioscience) followed by streptavidin beads (Dynabeads, Life Technologies). Finally, highly purified nonhematopoietic cells were obtained through flow cytometry and sorting (FACS Aria II, BD Biosciences) as a population lacking CD45 and Ter-119 expression.

**Quantitative PCR Analysis**

For IL-1α, TNF-α, and IFN-γ RT-PCR, $1.2 \times 10^5$ stromal cells were collected; for Tumor Necrosis Factor Receptor 1 (TNFR1), riboflavin kinase, and p22phox RT-PCR, $5.4 \times 10^5$ KSL cells were collected, by flow cytometry and subjected to RNA isolation (RNaseasy MicroKit; QiAGEN, Venlo, Netherlands). cDNA samples were synthesized using High Capacity cDNA Reverse Transcription Kits (Life Technologies). For quantitative PCR (qPCR) reactions, samples were prepared in triplicate and reactions were run for each sample in 20 μl of mixture including 2 μl of cDNA, Eagle Taq Master Mix with ROX (Roche Life Science, Basel, Switzerland), 10 μM of probe (from a Roche-Universal Probe Library, Basel, Switzerland), and 10 μM of the following primers ($5' \rightarrow 3'$), with IL-1β: forward, agtggacgacccaaag/reverse, agctggatgctctcatcagg; TNF-α: forward, cttgagcccagttgcag/reverse, ttggagatcatgcttggg; IFN-γ: forward, acgtggaggaagtcagagc/reverse, tctagacttaacagctg; TNFR1: forward, ggaaagtctcatcaagcagger, reverse, agaactcactaggttccttt; riboflavin kinase: forward, tcaacgccagagcagcagcag, reverse, gagtcatcttgctcaaatcataag; molecular mass: 5,275.97 Da), was used as control. Both PepTNFR1 and PepScr were applied (60 μM) for 4 hours to test cells before stimulation by TNF-α. ROS production was measured 48 hours after TNF-α addition.

**Statistics**

Two groups were compared with a Mann–Whitney test, whereas multiple groups were compared using one-way ANOVA followed by a Tukey’s pos hoc test. A value of $p < .05$ was considered statistically significant.

**Study Approval**

All animal experiments were performed under the approval of the Institutional Animal Care and Use Committee of the Institute of Medical Science, University of Tokyo.

**Results**

**Initial In Vivo Exposure to Ongoing Inflammation in an Irradiated BM Environment Affects Graft-HSCs’ Reconstitution Ability**

We first tested if the recipient BM environment would affect graft-HSCs differently depending on interval between total body irradiation (TBI) and transplantation. To this aim, test HSCs (purified CD34+/low cKit+/Sca-1− Lineage-marker− cells, CD34+ KSL cells hereafter) obtained from Ly5.1+ C57BL/6 (B6) mice were transplanted at a dose of 50 cells together with $1 \times 10^5$ competitor BM cells (from Ly5.1−/5.2− B6 mice) into primary recipient mice (Ly5.2− B6) irradiated at different times (Fig. 1A, Primary transplantation). All mice transplanted 5 days after TBI (“day 5” group) soon died, precluding subsequent experiments. Some mice also died in a group transplanted 3 days after TBI (“day 3” group); however, serial analysis of donor cell chimerism was feasible in the survivors for up to 24 wks, allowing comparison with another group transplanted on the day of TBI (“day 0” group). As shown in Fig. 1B, left, no significant difference in donor cell chimerism existed between groups. We interpreted this as reflecting equality of recipient BM environmental
We thus purified Ly5.1 hematopoietic stem/progenitor cells (HSPCs) from these primary recipient mice and competitively transplanted 1,000-cell aliquots into secondary recipient mice to compare reconstitution ability among HSCs that had experienced the TBI-BM environment under different conditions (Fig. 1A, Secondary transplantation). Remarkably, HSPCs initially transplanted 3 days after TBI ("day 3") contributed significantly less to hematopoietic reconstitution in the secondary recipients than did "day 0" HSPCs (Fig. 1B, Secondary), indicating impaired stem cell functions in the former.
Short-Term Exposure to Irradiated BM Impairs graft-HSCs’ Reconstitution Ability in a Time Dependent Manner

We next sought to test how “short-term” (~24 hours) exposure to an irradiated BM environment could affect graft-HSCs. To this aim, we developed new transplantation experiments (Fig. 2). In brief, purified HSCs alone (400 cells) were first transplanted into recipient mice at different times after lethal-dose TBI (Fig. 2A, 2B, In vivo HSC exposure transplantation). After 24 hours, when a substantial proportion of transplanted cells was thought to reside within BM, whole-BM cells (equivalent doses were ensured on a bone-volume basis, thereby taking into account variable cell yields after TBI. See Materials and Methods) were competitively transplanted into lethally irradiated recipient mice. In this experiment, transplanting whole BM cells ~24 hours after HSC infusion with competitor cells into another cohort of irradiated mice permits assessment of reconstitution ability in test HSCs residing in BM of the initial recipient (Fig. 2A, 2B, Primary transplantation). As shown in Fig. 2C, achieved chimerism tended to decrease with interval between TBI and exposure to the irradiated BM environment; thus chimerism was least with HSCs exposed to irradiated BM between 48 and 72 hours after TBI (d2-3), while with those exposed to irradiated BM in the first 24 hours after TBI (d0-1), chimerism was greatest (Primary). When HSCs were serially transplanted, loss of contribution to hematopoiesis became evident with exposure late after TBI (Fig. 2C, Secondary, d2-3 and d3-4). Of importance is that the first two groups also clearly differed; in secondary transplantation, HSCs exposed to BM for the first 24 hours after TBI (d0-1) outperformed those exposed for the second 24 hours after TBI (d1-2). These results indicate collectively that HSCs’ reconstitution ability can be impaired within an “inflamed” BM environment even during a short-term (~24 hours) time window.

TNF-α Plays a Role in the Impairment of Transplanted HSCs by an Inflammatory BM Environment

For an overview of BM environmental change caused by TBI, we performed comprehensive gene expression analysis in BM-resident stromal cells considered to constitute the HSC niche. Expression of genes encoding certain inflammatory cytokines and chemokines rose one day after TBI, quickly returning to basal levels (Fig. 3A). We focused on 3 major inflammatory cytokines, IFN-γ, IL-1β, and TNF-α (Fig. 3B); induction of gene expression for the latter two was confirmed by re-analysis (Fig. 3C). To compare the effects of these cytokines on HSCs, we conducted in vitro HSC colony forming assays as previously described [13, 21]. Only TNF-α inhibited colony formation of HSCs in a dose dependent manner. The other 2 cytokines’ effects were marginal (Fig. 3D). To examine in vivo relevance of TNF-α’s role, we next used in vivo short-term HSC exposure assays to test if deletion of host-derived TNF-α could preserve HSC functions, comparing TNF-α KO BM with wild type BM (Fig. 4A). As shown in Fig. 4B, left, graft-HSCs exposed to TNF-α KO BM tended to achieve greater chimerism, although no statistical difference existed between the groups’ results (WT vs. TNF-α KO, Primary). Interestingly, however, this difference was clearly magnified upon secondary transplantation, with better preservation of reconstitution ability in graft-HSCs initially exposed to inflammatory BM lacking environment-derived TNF-α (Secondary). Detailed chimerism analysis revealed that the absence of TNF-α in inflammatory BM favored lymphoid potential more than myeloid potential in the test HSCs (Supporting Information Fig. 3). We concluded, in summary, that TBI provoked inflammation within BM and that TNF-α could impair graft-HSC function even in a short-term time window in a time-dependent fashion.

TNF-α Induces ROS Accumulation in HSPCs

We then sought to elucidate mechanisms by which TNF-α impaired HSCs’ reconstitution ability. TNF-α stimuli activate Nicotinamide Adenine Dinucleotidemono Phosphate Hydride (NADPH) oxidase, with ROS produced through coupling riboflavin kinase to NADPH oxidase [20]. While accumulation of ROS results in DNA damage and functional impairment in HSCs [22], a relationship between TNF-α and ROS in these cells remains to be investigated. We first confirmed expression of key components in the putative complex of TNF-α:ROS signaling in HSPCs (Fig. 5A) and accordingly determined whether TNF-α stimulation led to excessive production of ROS in highly purified murine HSPCs by culturing them with or without TNF-α stimulation for up to 48 hours and staining them with dichlorodihydrofluorescein (DCF) to quantify the accumulation of ROS (Fig. 5B). As shown, TNF-α induced ROS production in HSPCs in a dose- and time-dependent manner (Fig. 5C, 5D). That TNF-α stimulation induced HSPCs to produce ROS was confirmed more specifically using HySox [19], a stable, auto-oxidation—resistant novel fluorescent probe uniquely specific for hypochlorous acid (Supporting Information Table).

Correlation of Elevated ROS Levels with Impairment in Reconstitution Ability of HSCs after Exposure to TNF-α

We next sought to assess if a causal relationship existed between TNF-α-mediated ROS accumulation and impaired reconstitution ability of HSCs. We first confirmed that cultivation of HSCs with TNF-α for 48 hours lowered their reconstitution ability in competitive repopulation assays (Supporting Information Fig. 1A, 1B). We then compared reconstitution abilities of HSCs between groups exhibiting different levels of ROS using flow-cytometry sorting (Supporting Information Fig. 2A). As shown in Supporting Information Fig. 2B, competitive repopulation assays revealed that reconstitution ability was less in HSCs with high levels of ROS (DCF-high) than in HSCs with low/medium levels of ROS (DCF-low/med). Interestingly, the difference was highly significant with respect to lymphoid reconstitution, but not myeloid reconstitution. These results suggest that short-term-exposure to TNF-α affects HSCs’ reconstitution ability through induction of ROS.

Inhibition of TNF-α Mediated ROS Accumulation is Feasible by Simple Pre-Incubation of HSPCs with Reagents

As ROS accumulation in response to TNF-α within an inflammatory BM environment quickly reduces graft-HSCs’ reconstitution ability, we hypothesized that to inhibit ROS production even for a short-term might improve transplantation outcomes. It was reported that the TNF receptor 1 (TNFR1) blocking peptide (PepTNFR1) specifically blocked NADPH oxidase-mediated ROS production in cells after stimulation with TNF-α [20]. We thus tested if PepTNFR1...
Figure 2. The influence of short-term exposure to an irradiated BM environment on reconstitution ability of HSCs. (A): Schematic representation of a newly designed experiment to test how in vivo short-term (~24 hours) exposure to irradiated BM affects reconstitution ability of HSCs. In vivo HSC exposure transplantation. Test HSCs (400 cells per mouse, Ly5.1<sup>+</sup> CD34<sup>−</sup> KSL cells) were transplanted alone intravenously into lethally irradiated recipients (B6 Ly5.2<sup>−</sup>, n = 3 for each group) at indicated times (0, 24, 48, 72 hours after irradiation). Twenty-four hours later, BM cells were harvested from 6 bones per mouse (femora, tibiae, and pelvic bones) and pooled to prepare a test cell population from all 3 mice that contained BM-homed graft-HSCs, thus “exposed to an irradiated BM environment” within the given time windows. Primary transplantation. Test BM cells from the pools described above were competitively transplanted with 2 × 10<sup>5</sup> whole BM cells obtained from B6 Ly5.1<sup>−</sup>/5.2<sup>+</sup> F1 mice into lethally irradiated mice (B6 Ly5.2<sup>−</sup>) (n = 5 for each group). Because the numbers of cells recovered from irradiated BM varied greatly, and because sorting graft-HSCs homed to BM was not realistic, we simply divided pooled test BM cells into 5 fractions, each of which was given to a single recipient mouse. In mice that survived, donor cell (Ly5.1<sup>+</sup>) chimerism was sequentially analyzed up to 24 weeks. Secondary transplantation. BM cells were collected at 24 weeks from all available primary recipients in each group. These cells were transplanted into lethally irradiated mice (5 × 10<sup>5</sup> per mouse; n = 10, B6 Ly5.2<sup>−</sup>). In mice that survived, donor cell chimerism was sequentially analyzed up to 20 weeks. (B): Exposure to irradiated BM environment between day of total body irradiation (TBI; day 0) and one day afterward, “d0-1”; between one day after TBI and one day afterward, “d1-2”; between two days after TBI and one day afterward, “d2-3”; between three days after TBI and one day afterward, “d3-4.” The orange contour of putative inflammation can be divided into 4 portions, day by day, to understand variation in BM milieu after irradiation in terms of variation in effects on HSC abilities. (C): Values of %donor chimerism in individual recipients at indicated times are shown. Left: Primary transplantation (n = 5, with some loss). Right: Secondary transplantation (n = 10). Mean values are indicated as bars. Data were analyzed by one-way ANOVA with Tukey’s multiple comparison test. ***p < .001. Abbreviations: ANOVA, analysis of variance; BM, bone marrow; HSC, Hematopoietic stem cell, ns, not significant.
Figure 3. Induction of inflammatory cytokine synthesis in BM-resident stromal cells by total body irradiation and a causal role for TNF-α in impairing reconstitution ability of HSCs exposed to an inflammatory BM environment. Total RNA samples collected from BM-resident stromal cells with or without TBI were subjected to high sensitivity DNA microarray assays. (A): A heatmap representation of microarray data clustered for the set of inflammation-related genes. UT, untreated (unirradiated); 9.5 Gy day1, collected 1 day after TBI; 9.5 Gy day3, collected 3 days after TBI. Note that IL-1β (Il1b) and TNF-α (Tnf) are similarly located at the top in a map (indicated). (B): Dot plots showing relative expression of genes after irradiation in comparison with baseline levels (Unirradiated). Top: day 1 after TBI vs. Unirradiated; bottom: day 3 after TBI vs. Unirradiated. Plots for IL-1β and TNF-α are shown in yellow. Weakness of signals precluded construction of a parallel plot for IFN-γ expression. (C): qPCR analysis of gene expression in mouse BM stromal cells in relation to TBI. Shown are mean expression levels of each indicated cytokine gene after TBI (day 1 and day 3 after 9.5 Gy) relative to the baseline levels [Day 0 (Unirradiated)]. Mean ± SD (measured in triplicate). Data were analyzed by one-way ANOVA with Tukey’s multiple comparison test. ***p < .001. (D) Single-cell colony assays in the presence of multiple cytokines. Varying concentrations of inflammatory cytokines were included as indicated. Shown are colony numbers with classification by colony sizes. Abbreviations: BM, bone marrow; qPCR, quantitative PCR; TBI, total body irradiation.
could block ROS accumulation induced by TNF-α also in our experimental settings. As shown, pre-incubation (~4 hours) of murine HSPCs with PepTNFR1, but not with a scrambled control peptide (Scr), inhibited TNF-α-mediated ROS accumulation; this was confirmed using 2 independent dye-indicators, DCF and HySOx (Fig. 6A, 6B).

Figure 4. Testing a causal role for TNF-α in impairment of HSCs’ reconstitution ability within an irradiated BM environment. (A): Schematic representation of an experiment to test whether the absence of TNF-α from an irradiated BM environment improves graft-HSCs’ reconstitution ability. An in vivo short-term HSC exposure assay was carried out as shown in Fig. 2 with some modifications. In vivo HSC exposure transplantation. As inflammation kinetics might differ between WT and TNF-α KO backgrounds, exposure time was set at 48 hours instead of 24 hours. Test HSCs (400 cells, Ly5.1+ CD34+ KSL cells) were transplanted alone intravenously into lethally irradiated recipients (WT or TNF-α KO, B6 Ly5.2−, n = 4 for each group) at 48 hours after irradiation. Forty-eight hours later, BM cells were harvested from 6 bones per mouse (femora, tibiae, and pelvic bones) and pooled to prepare a test cell population from all 4 mice that contained BM-homed graft-HSCs. For primary transplantation, test BM cells from the pools were competitively transplanted with 2 × 10^5 B6 Ly5.1+/5.2− F1 whole BM cells into lethally irradiated mice (B6 Ly5.2−) (n = 6 for each group). Similarly as described in Fig. 2 legend, we divided pooled test BM cells into 6 fractions, each of which was given to a single recipient mouse. In mice that survived, donor cell (Ly5.1+) chimerism was sequentially analyzed up to 26 weeks. (B): Preservation of reconstitution ability in HSCs after in vivo exposure to inflammatory BM environment lacking TNF-α. Donor cell chimerism assessed over time in a competitive repopulation assay in primary and secondary recipients (left and right, respectively). Note that reconstitution ability of HSCs exposed to TNF-α (-) BM (TNF-α KO) at secondary transplantation is greater than that of HSCs exposed to wild type BM (WT). Mean values are indicated. Data were analyzed by Mann–Whitney test. **p < .001. Abbreviations: BM, bone marrow; HSC, Hematopoietic stem cell; KSL, cKit+, Sca-1+, Lineage-marker−; ns, not significant; WT, wild type.
Then, to determine if short-term inhibition of ROS accumulation in graft-HSCs had potential to improve transplantation outcomes, we tested the effects of HSC pre-incubation with a representative antioxidant NAC, by which sort of protective effects were demonstrated on HSCs in serial transplantation experiments when given systemically to recipients for long-term
As expected, continuous incubation of HSPCs with low concentration (0.1 mM) of NAC significantly inhibited TNF-α-mediated ROS accumulation at 48 hours (Fig. 6C, 0.1 mM). Of note is that a pre-incubation method (4 hours) was shown also applicable to NAC (4 mM), with lowered ROS levels evident even 48 hours after TNF-α stimulation.

Pre-Transplantation Incubation with NAC Protects Graft-HSCs from Loss of Long-Term Reconstitution Ability by Inflammatory BM Environment

We finally tested if reconstitution ability in HSPCs was protected in inflammatory BM by pre-transplantation incubation with NAC. In these experiments, test cells were left unprotected or protected by NAC pre-treatment (0.1 and 4 mM, 4 hours), and transplanted into recipient mice lethally irradiated at day-2, competitively with “non-protected” BM cells (Fig. 7A). As shown, test cell chimerism in primary recipients showed tendency to decline over time in a control group (Fig. 7B, Primary transplantation, Control). In contrast, some recipient mice seemed to be showing some protective effects on graft-HSCs by NAC pre-treatment in both 0.1 and 4 mM groups, although only one occasion reached statistically significant difference (%Ly5.1 chimerism in T cells at 16 weeks, Control vs. 4 mM NAC). Remarkably, protective effects became apparent upon secondary transplantation as shown by higher donor-cell chimerism in recipients of “protected” HSCs (NAC) than in those of nonprotected HSCs (Control); the results were highly reproducible in independent experiments (Secondary transplantation, Fig. 7B and Supporting Information Fig. 4). Interestingly, NAC effects by pre-incubation were visible even with 0.1 mM concentration. Moreover, two NAC concentrations affected HSCs in a distinct manner: low concentration favored lymphocyte reconstitution.
Figure 7. Protection of graft-HSCs from inflammatory BM environments. (A): Testing in vivo protection of graft-HSCs from an inflammatory BM environment. Highly purified B6-Ly5.1 KSL cells mock-treated (nonprotected) or pre-treated with NAC (protected) were subjected to a modified competitive repopulation assay (transplantation 2 days after irradiation). Note that competitor B6-Ly5.1/5.2 BM cells were “not protected” so that preservation of reconstituting ability in test HSCs would lead to higher donor chimerism values. (B): Graphic representation shows a trend of protective effects by NAC in primary recipients (Primary transplantation), which became visible after serial transplantation (Secondary transplantation). Mean values are shown. Data were analyzed by one-way ANOVA with Tukey’s multiple comparison test. *p < .05, **p < .01, ***p < .001. Abbreviations: ANOVA, analysis of variance; BM, bone marrow; HSC, Hematopoietic stem cell; NAC, N-acetyl-L-cysteine; ns, not significant; TBI, total body irradiation.
better, whereas high concentration helped myeloid cell reconstitution more. This observation was also highly reproducible (Fig. 7B and Supporting Information Fig. 4).

DISCUSSION

In allogeneic BM transplantation (BMT), preconditioning induces inflammation in recipients’ BM microenvironment [24]; TBI stimulates release of inflammatory cytokines from macrophages [24] and of TLR ligands from bacterial flora [25]. Moreover, anti-tumor chemotherapy may sensitize tissues to the toxic effects of conditioning [26]. Such inflammation is of particular significance in relation to graft-versus-host disease (GvHD) [24–26]. However, the possible effects of such inflammation on transplanted HSCs/HSPCs have not been formally examined. We thus explored in a BMT setting the new strategy of stem cell protection from preconditioning-related inflammatory changes in the BM environment.

The effects of inflammatory cytokines on HSCs are controversial [9, 10, 27–31]. TNF-α primarily inhibits growth and induces apoptosis of HSCs in both human [10, 27, 28, 31] and mouse [29, 30, 32] systems; our results in mouse HSCs/HSPCs were overall consistent with those reports. Other researchers report different effects; in a TNF-α pathway, TNF Receptor Superfamily1a might be crucial for maintenance of HSCs [9, 33, 34]. That stimulation of progenitors via TNFR1 signaling, with activation of the caspase cascade, supports better engraftment [35] indicates that TNF-α effects must be evaluated cautiously in light of specific experimental and clinical conditions. Furthermore, other inflammatory cytokines are also necessary to support HSC function [3, 4].

Our study focuses on adverse effects on transplanted HSCs of an inflammatory BM environment, an inevitable consequence of TBI pretreatment in HSCT. Although the influence of serum TNF-α levels on graft cells is clinically appreciated [1, 26], detailed analysis of BM levels of inflammatory cytokines have not yet been done; nor have effects of preconditioning on purified HSCs been tested, and measures to improve transplantation outcomes based on “stem cell protection” have not been sought. To our knowledge, ours is the first demonstration of a link between TNF-α and ROS accumulation that affects the reconstitution ability of purified HSCs/HSPCs.

The relationship between HSCs and ROS is of great interest. Hypoxia in the BM niche maintains HSCs’ self-renewal activity [36], and a ROSlow HSC population exhibited higher self-renewal activity than a ROShigh population [37]. Accumulation of ROS resulted in DNA damage and functional impairment of human HSPCs [22]. In addition, ROS levels in the BM environment and not in graft-HSCs may affect transplanted human HSPCs [38]. These observations generally highlight adverse effects of ROS on transplanted HSCs/HSPCs, but other data suggest that ROS enhance early hematopoietic reconstitution after transplantation [37, 39]. We have recently demonstrated in a comprehensive in vitro study that inflammatory cytokines alter ROS levels variously in human HSCs/HSPCs, which in turn seem to affect cellular fates [40]. It might be intriguing that in our HSC protection experiments, different NAC concentrations did exhibit distinguishable protective effects on its reconstitution ability with one supporting lymphoid potential better while the other favoring myeloid repopulation. An in vivo short-term HSC exposure assay also showed bias in myeloid/lymphoid lineages in secondary recipients when reconstitution ability of graft-HSCs was preserved by the absence of TNF-α. We thus believe it crucial to regulate ROS levels within appropriate windows at varying times to regulate outcomes in a favorable way in transplantation medicine.

Several issues still remain to be addressed. For example, although we have demonstrated that stem cell protection applies to murine HSPCs, transplantation experiments with human HSPCs with or without protection have not been conducted. This requires xenotransplantation with immunodeficient mice and allows only very low-dose TBI, most likely not enough to induce meaningful levels of TNF-α synthesis. Other approaches will be needed, such as using mice that permit timely BM induction of TNF-α in the absence of lethal TBI while still accepting human hematopoiesis. Similarly, to test stem cell protection in allogeneic BMT will be interesting. We here used a congenic transplantation system to allow a proof-of-concept study while minimizing variables such as GvHD, which might affect hematopoietic reconstitution by several unidentifiable factors. Inflammation may be more severe in allogeneic than in autologous transplantation, due to disparity between donor and recipient MHC types, with systemic and sustained elevation of TNF-α; it thus remains to be determined whether the current stem cell protection method still exhibits visible benefits on graft-HSCs.

We believe that in combination with other strategies such as amplification of HSCs, some of which are already being tested in clinical trials [41–43], establishment of stem cell protection measures will help improving transplantation medicine. Notably, Mantel et al. reported that the mitochondrial respiratory dysregulation in murine HSCs/HSPCs would cause ROS overproduction leading to their functional defects [44]. Furthermore, they also demonstrated that the measures to prevent such unfavorable events during collection and processing could benefit HSC recovery [45]. We thus expect that the two measures will work cooperatively to protect HSCs, at the stage ex vivo by the latter, whereas in vivo by ours. Overall, the cumulative effort to optimize the appropriate use of all these HSC manipulation techniques in combination will eventually lead to better engraftment and reconstitution kinetics in transplantation, rescuing many patients who require HSCT.

CONCLUSIONS

We here provide a proof of benefit that stem cell protection measures against TNF-α-mediated ROS accumulation in the context of transplantation will eventually help in combination with other available approaches better engraftment and improved reconstitution kinetics, thereby ameliorating outcomes of HSCT.

ACKNOWLEDGMENTS

We thank K. Maruyama (GORYO Chemical) for technical advice on the use of HySOx and Dr. A. S. Knisely for critical reading of the manuscript. We also thank Dr. H.-T. Lin for his advice on the graphical abstract. This work was supported in part by JSPS KAKENHI 21249059, 24659127, 15K15109.
AUTHOR CONTRIBUTIONS

T.I.: Conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing; S.S.: Conception and design, collection and/or assembly of data, data analysis and interpretation; C.-Y.L.: Collection and/or assembly of data; S.Y.: Conception and design, data analysis and interpretation; S.K.: Provision of study material or patients; Y.I.: Provision of study material or patients; M.N.: Data analysis and interpretation; Y.T.: Conception and design; M.H.: Administrative support, final approval of manuscript; H.N.: Administrative support, final approval of manuscript; M.O.: Conception and design, data analysis and interpretation, manuscript writing, final approval of manuscript.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.
reactive oxygen species in the early steps of adult hematopoietic reconstitution. Blood 2010;115:443–452.
40 Ishida T, Yamazaki S, Nakauchi H et al. Reactive oxygen species in hematopoietic stem cells affect culture outcomes under inflammatory conditions. Open J Hematol 2015;6:7.
41 Boitano AE, Wang J, Romeo R et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010;329:1345–1348.
42 Hagedorn EJ, Durand EM, Fast EM et al. Getting more for your marrow: Boosting hematopoietic stem cell numbers with PGE2. Exp Cell Res 2014;329:220–226.
43 Hoggatt J, Singh P, Sampath J et al. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009;113:5444–5455.
44 Mantel C, Messina-Graham S, Moh A et al. Mouse hematopoietic cell-targeted STAT3 deletion: Stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype. Blood 2012;120:2589–2599.
45 Mantel CR, O’leary HA, Chitteti BR et al. Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock. Cell 2015;161:1553–1565.

See www.StemCells.com for supporting information available online.